BioMedWire Stocks

Study Suggests Coronavirus Vaccine May Be Linked to Temporary Changes in Menstrual Cycles

A new study has looked into the connection between menstrual health and vaccination against severe coronavirus infections. The researchers were focused on disproving reports that the coronavirus vaccine could affect menstruation cycles of women of reproductive age. These unfounded claims fostered vaccine skepticism among women as well as the general public, despite the lack of sufficient systematic research on the effects of the coronavirus vaccine on menstrual health.

For their study, the researchers looked into the correlation between the SARS-CoV-2 infection and COVID vaccination with changes in the menstrual cycle features of more than 3,000 premenopausal healthcare workers. The researchers tracked these workers, all of whom were female and resided in the United States and Canada. They sent follow-up questionnaires to every participant twice a year in the 10-year period between 2011 and 2021.

These female healthcare workers also took part in supplementary surveys regarding the coronavirus pandemic every month and every quarter from April 2020 through November 2021. These surveys allowed participants to self-report their history of positive coronavirus tests, their COVID vaccination status and the vaccine they received.

In addition, the researchers also collected information on the length and regularity of every participant’s menstrual cycle then assessed any shift in menstrual cycle features using logistic regression or multinomial logistic models.

After they had controlled for sociodemographic and behavioral characteristics, the researchers discovered that women who had received coronavirus vaccinations had a heightened risk of prolonged menstrual cycles in comparison to those who weren’t vaccinated. They also found that women with irregular, short or long pre-vaccination menstrual cycles were likely to experience a short-term increase in the duration of their menstrual cycles after they had received the coronavirus vaccine.

The researchers explained that mRNA and Adenovirus-vectored coronavirus vaccines were linked to this change in menstrual cycles.

However, they also observed that the SARS-CoV-2 infection wasn’t linked to any modification in regular features of a menstrual cycle, observing that the temporary impact of the coronavirus vaccines could have been caused by an immune reaction to the SARS-C-V-2 infection.

In their conclusion, the researchers noted that the coronavirus vaccines could be linked to short-term alternations in menstrual cycle length, especially in women whose cycles were irregular, short or long prior to vaccination. This, they noted, highlighted the importance of tracking menstrual health throughout clinical studies on vaccination.

The study’s findings were reported in the “American Journal of Obstetrics and Gynecology.”

The impact of the vaccine that keep being uncovered show why companies such as Odyssey Health Inc. (OTC: ODYY) conduct ongoing research and keep tweaking their products in order to address the emerging realities surrounding different illnesses and treatments.

NOTE TO INVESTORS: The latest news and updates relating to Odyssey Health Inc. (OTC: ODYY) are available in the company’s newsroom at https://ibn.fm/ODYY

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

Breakthrough Treatment for Lung Cancer Uses Mitochondria to Supercharge Immune Cells

Researchers in China have discovered a way to supercharge the treatment of lung cancer by…

4 days ago

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF): The Cancer Detection Revolution That Could Make Breast Cancer Deaths Preventable

Izotropic’s IzoView Breast CT Imaging System represents a breakthrough in dedicated breast imaging technology, addressing…

4 days ago

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) Advancing Next-Gen Breast Cancer Imaging

Breast cancer continues to be the most commonly diagnosed cancer among U.S. women, excluding nonmelanoma…

5 days ago

How to Rebuild Trust in the US Healthcare System

A recent survey undertaken by Gallup in 2025 found that since 2021, there has been…

5 days ago

Lantern Pharma Inc. (NASDAQ: LTRN) Completes Japanese Enrollment for LP-300 Phase 2 HARMONIC(TM) Trial Ahead of Schedule

The trial targets never-smoker non-small cell lung cancer (“NSCLC”) patients, a group with limited treatment…

5 days ago

Lantern Pharma Inc. (NASDAQ: LTRN) Launches AI Tool to Predict Efficacy of Cancer Drug Combinations

Lantern Pharma has introduced an AI-powered module within its RADR(R) platform to assess DDA-DDRi combination…

5 days ago